MedTrace Logo

Therapeutic Instillation of Mistletoe

NCT02106572 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 174

Last updated 2026-05-22

No results posted yet for this study

Summary

The aim of this phase III study is to assess the efficacy of abnobaVISCUM® 900 compared with Mitomycin C (MMC) monotherapy in patients with superficial bladder carcinoma by evaluation of the time to tumor recurrence. Secondary objective is to evaluate the safety of abnobaVISCUM® 900, in particular, to compare the toxicity of the two treatments. Another secondary objective is the treatment efficacy as measured by calculated prognosis for recurrence and progression after 1 year, the tumor grading in case of a recurrence and by measurement of Quality of Life.

Conditions

  • Superficial Bladder Cancer

Interventions

DRUG

abnobaVISCUM 900

intravesical instillation of abnobaVISCUM 900 13 times during treatment period

DRUG

Mitomycin C

intravesical instillation of Mitomycin C 10 times during treatment period

Sponsors & Collaborators

  • Abnoba Gmbh

    lead INDUSTRY

Principal Investigators

  • Jochen Hess, Prof. Dr. · Chief Medical Officer of the Urological Clinic of the University Hospital Essen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2026-03-24
Completion
2026-04-24

Countries

  • Egypt
  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02106572 on ClinicalTrials.gov